After renal transplant due to immunomodulation with drugs and exposure to various viruses, there is increased incidence of post-transplant malignancy. Although kidney transplantation has less Standardized incidence ratio (SIR) of malignancy as compared to lung and liver transplant, they still contribute to overall morbidity. Infact, there are discussion to include post-transplant malignancy as one of the composite outcomes in various clinical trials1. The overall cumulative incidence of any de-novo malignancy in a UK study population shows that transplanted patients have an increased risk2. In most of the western countries after cardiovascular disease, cancer is the most common cause of death with a functioning graft3.
Most of the malignancies occur de novo and less than 1% of the malignancies are pre-existing before transplantation. Cancer transmission from donor is rare although it is important to take informed consent prior to transplantation. Cumulative incidence of malignancy ranges from 10-15% after 15 years of transplant.4The incidence varies with respect to type of cancer. The overall SIR(standardized incidence ratio) for various cancers is high in renal transplant recipients. The data from the UK registry show that there has been an increase in the incidence of Non melanoma skin cancers(16.6%), Kaposi’s sarcoma(17.1%), PTLD(12.5%), oral cancers(65%), Anogenital cancers(10%)2. Certain cancers like breast and prostate cancers are very rare post renal transplantation5. Once the cancer is diagnosed the overall all-cause mortality in these patients have increased
Cancer occurs at a younger age compared to the general population in renal transplant patients.6The survival of cancer in various stages is also lower as opposed to general population.6 The average latency period for various malignancies is 12 – 36 months after transplantation. The latency period is longer in paediatric transplantation as the lesions of cancer develop in adulthood with the exception of primary EBV associated PTLD.7Traditional risk factors are increasing age, male gender, smoking and prolonged sun exposure are common to post renal transplant patients. Certain cancers like multiple myeloma and renal cell carcinoma due to ADPKD maybe pre-existing in CKD patients itself.8 Certain geographic incidences exists. Hepatocellular Carcinoma due to hepatitis B is more common in Taiwan renal transplant patients due to endemicity of hepatitis B in Taiwan. Europe, North America and Australia record higher incidence of non-melanoma skin cancers, PTLD and Lip cancers. The Middle East and Asian countries report a higher incidence of urogenital cancers and bladder cancer.9
The figure below summarizes the pathogenesis of malignancy in renal transplant recipients.
It is the most common type of cancer in renal transplant population. Squamous cell carcinoma, Basal cell carcinoma,Kaposi’s sarcoma, malignant melanoma are the common skin cancers encountered. Non melanoma skin cancers account for 90-95% of all the skin cancers.14 Squamous cell carcinoma is more common in SOT recipients than basal cell carcinoma. The risk of Squamous cell carcinoma is 250 times as compared to the general population.14 In general population basal cell carcinoma is more common than squamous cell carcinoma. But a study from Ireland published in 2019, quoted a decline in the overall incidence of keratinocytic carcinoma in renal transplant recipients.15Both SCC and BCC have sun exposure as a risk factor. Other risk factors from the same Irish study include pre transplant skin lesions, thoracic organ transplant, white race, age > 50 years, post-transplant premalignant skin lesions.15UVA and UVB rays have been implicated in pathogenesis of skin cancer. The intensity of the UV rays is peak in the afternoon and the rays have to travel less distance to reach the individual at noon. Hence avoidance of peak noon and 2 hours later is advised for all renal transplant recipients. Sun screen with SPF of 50 and 5 stars rating to prevent exposure to UVB and UVA is advocated for all patients. The DNA damage induced by the UV rays is not able to get repaired due to immunosuppressive medications. UV protective clothing like silk is better than cotton as finer the weave better is the protection. The treatment of SCC and BCC are wide local skin excision. Topical treatment for in situ carcinoma and small tumours include topical fluorouracil and imiquimod, photodynamic therapy and electrodessication. Patients should be warned to screen themselves by skin examination and report if any new lesion occurs. For metastatic SCC, systemic chemotherapy and immunotherapy are recommended. BCC is a local skin tumour and it rarely spreads.
The incidence of Kaposi’s sarcoma is more in SOT recipients especially in few racial groups like Mediterranean, Africa and Arabian population; with incidence of 100 times more than in general population. It occurs due to reactivation of Human Herpes virus 8. Dissemination with visceral involvement is common and it indicates a bad prognosis. Kaposi’s sarcoma has excellent response to CNI withdrawal and even regression of the malignancy is reported after switch to mTOR inhibitors.16,17The study from NEJM in 2005 showed that 3 months after initiation of mTOR inhibitors all the lesions of kaposi’s disappeared and 6 months later biopsy of skin lesion showed resolution of the cancer.16
The incidence of malignant melanoma is 5 to 8 times as compared to general population. Studies show poor prognosis of the melanoma in renal transplant patients. Pre transplant melanoma, white race, age>50 years are the main pre transplant risk factors. Surgical wide excision is the treatment of choice.18
Carcinoma cervix accounts for 3% of all post-transplant malignancies in renal transplant recipients and it is the most common cancer after skin cancer in women.19 Oncogenic virus mainly human papilloma virus mainly 16 and 18 are responsible for cervical cancer in many of the patients. Cervical intra epithelial neoplasia is 16 times more common in high risk transplant individuals due to HPV than age matched controls.20 Low risk HPV infection causes viral warts and high risk HPV infection are associated with cervical intra epithelial neoplasia.
Routine cancer screening is beneficial in general population and the same is extrapolated to the transplant patient. WHO recommends HPV DNA testing as first choice of screening for cervical cancer prevention. Males and females aged between 9-25 years are recommended universally for HPV vaccination. Ideally HPV vaccines are recommended prior to renal transplant as the immunological titres of antibody are better prior to transplant. Many centres report HPV vaccination in kidney transplant recipients with variable efficacy.21,22
Renal transplant patients have 4 fold increases in the incidence of bladder and renal carcinoma. The incidence of bladder cancer is also increased in those with BK virus infection.23 The idea that BK virus can cause carcinoma of the urinary tract has been found when BK virus genome has been found to be integrated with cancer genes in few urothelial carcinoma in few studies.24But there are no casual associations between BKV and urothelial cancer. They are limited to case series and reports only. Carcinoma of the prostate is not increased in renal transplant population. There are case reports describing association between BK virus and Prostate cancer.25
The presence of ACD is more common in long term dialysis patient more than 3 years. Around 20% of ACD patients will progress to renal cell carcinoma. Renal cancer is around 8 times more common in renal transplant recipient. Routine screening for renal cancer is not recommended for transplant patients as per the American society of transplantation.26
PTLD is seen to affect 10% of all solid organ transplants. 90% of PTLD are associated with Epstein Barr virus (EBV) infection. EBV is very common infection in childhood and most of the children have been exposed to EBV by adulthood. After renal transplantation, there is reactivation of latent B cells due to T cell immunosuppression. Most PTLD are of the B cell type (95%) and EBV related. The cumulative incidence of PTLD in the first 10 year of transplant is around 1-2% of adults and 3% in paediatric transplants.27 There has been decreasing incidence of PTLD in Australia and New Zealand registry from 1995-2000 to 2005 by 8%.27 PTLD has bimodal distribution after transplant and incidence has been to highest in first 12 months and again later after 5 years only. The late PTLD are most often EBV negative.28The increase in the incidence of PTLD in paediatric recipients is due to primary EBV infection which occurs in the younger population. Overall mortality in PTLD is 50%. The risk factors for PTLD in renal transplant recipients are younger age, male gender, use of T cell depleting agents, negative EBV recipient with EBV positive donor, alemtuzumab use as induction agent are all risk factors for PTLD.27 The use of costimulatory blockade belatacept has been associated with development of PTLD especially cerebral PTLD.29The most common presentation of PTLD with high fever with night sweats and weight loss. The risk of mortality is 14 times higher after PTLD onset in renal transplant patients. Rituximab and use of cyclophosphamide, vincristine, prednisolone, doxorubicin have improved the overall survival at 60%.30
The general treatment for post treatment malignancy is reduction of immunosuppression and conversion or addition of mTOR inhibitors. mTOR inhibitors have anti-tumour effect by causing cell cycle arrest and hence it helps in reducing the growth of tumours. Specific treatment of individual malignancy depends on the cancer and its type. In astudy published in JASN 2006, sirolimus alone as compared to sirolimus, cyclosporine therapy was associated with decrease median time to BCC, non-skin cancers and SCC too.31In the CONVERT trail, 130 renal allograft recipients 6 to 120 months post-transplant who receiving cyclosporine or tacrolimus, were randomized to get sirolimus or to continue tacrolimus. The study demonstrated significantly lower malignancy rates at 12 and 24 months after transplant with no difference in biopsy proven rates of rejection and patient survival.32The use of immune check point inhibitors in renal transplant patients is not recommended outside case reports due risk of immune activation and rejection.
Penn in 1993 reported the time between pre transplant cancer occurrence and transplant influences the risk of recurrence after transplant.33 It was one of the seminal papers published in those times. But it added on to mortality of dialysis patients waiting in the list requiring a comprehensive decision of individual cases with medical oncology team.
Low risk breast cancer (stage1) and ductal carcinoma in situ for carcinoma breast no waiting time for transplant patients is needed. Stage 2 cancer breast require 1-2 years waiting time and Stage 3 cancer breast require 3-5 years waiting time before transplant. Stage 4 cancer breast patients are not candidates for renal transplant.34
Low risk colorectal cancer(in-situ cancer and Stage 1 cancer) have waiting time of 1 year. Stage 2 colorectal cancer has waiting period of 2 years. High grades of cancer have waiting time of 5 years and metastatic colorectal cancer are not considered to be transplant candidates.34
Cancer prostate with Gleason score less than 6 have low risk and no waiting time prior to transplant is recommended. High volume or those with intermediate to high risk cancer prostate with Gleason score of more than 7 and PSA>20ng/ml, waiting time for transplant is atleast 6 months after surgery if the disease is stable. There are recommendations to even consider transplant in metastatic cancer prostate after castration if there is cancer regression.34
Renal cell carcinoma T1a and T1b have no waiting time for renal transplantation. T2 RCC has waiting time for 2 years. T3 N0 M0 and T4 N0 M0 cancer have waiting time for minimum 2 years and then reassess before transplant. Any node positive any stage RCC renal transplant is contraindicated.34
Low and intermediate bladder cancer(solitary, <3cm, low grade) risk have waiting time for 6 months. High risk bladder cancer (multifocal, tumour>3cm,high grade T1 tumour) have waiting time of 2 years to assess the cancer activity stages.34
Basal cell carcinoma does not require waiting time for renal transplant as it is a local tumour without metastazing potential. Malignant melanoma in situ and those with breslow depth <1mm require waiting time of 2 years prior to renal transplant. Malignant melanoma with depth more than >1mm and multifocal tumour require prolonged waiting time of 5 years. Sqaunous cell carcinoma with nodal disease a waiting time of 5 years is suggested and so do tumours with peri neural invasion. High risk SCC(>2cm) with poor differentiation need a waiting time of 2 years prior to renal transplantation.34
It is a modality to consider if conventional treatment does not work for PTLD, lymphoma and leukaemia’s. The use of adoptive immunotherapy in solid organ transplant is controversial. It uses EBV specific cytotoxic T lymphocytes or donor lymphocyte infusion in attempt to prevent EBV proliferation in the B cells. Most of the data come from case series and retrospective reports from hematopoietic transplants. The same case series and reports quote remission in about 52-75% of the patients. The major complication of adoptive immunotherapy is acute and chronic grafts versus host disease.35 Modifications of adoptive immunotherapy to include calcineurin resistance in the gene of T cells have been tried.
Screening of cancer in transplant recipients: It is very essential to prevent cancer in transplant population to improve their overall survival. Routine screening for all cancers in not recommended and for few cancers the recommendations vary from one institute to another.36
Cancer in a renal transplant patient can devastate their life. The thin balance of immunosuppression reduction and graft rejection has to be looked into a transplant patient when considering “cure” for a cancer. Many guidelines are needed to ascertain the need for screening strategies in renal transplant patients.
Dr Balaji Kirushnan Consultant Nephrologist, Kauvery Hospital, Chennai
